XML 51 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Balances and Transactions With Related Parties and Key Officers
12 Months Ended
Dec. 31, 2022
Disclosure of transactions between related parties [abstract]  
Balances And Transactions With Related Parties And Key Officers

Note 24:  Balances and Transactions With Related Parties and Key Officers

 
  a.
Related parties consist of:
 
 
Clal Biotechnologies Industries Ltd.- Related party.
 
Directors of the Company.
 
  1.
Balances of related parties:
 
   
Other Payables
 
Related Party:
     
As of December 31, 2021
   
144
 
As of December 31, 2022
   
177
 
Directors:
       
As of December 31, 2021
   
96
 
As of December 31, 2022
   
130
 
 
  2.
Transactions with related parties:
 
Rental fee:
 
Year ended December 31
 
   
2022
   
2021
   
2020
 
Related party
   
457
     
469
     
446
 
 
 
Professional fee *:
 
Year ended December 31
 
   
2022
   
2021
   
2020
 
                   
Directors
   
484
     
375
     
272
 
Related party
   
63
     
85
     
54
 
     
547
     
460
     
326
 
Number of Directors
   
*10
     
8
     
8
 
 
  *
Not included share based compensation detailed in Note 19.
  *
During 2022 two members of the board of directors were replaced.
 
  b.
Key Officers:
 
  1.
Balances of Key Officers of the Company
 
   
Other Payables
 
Key Officers of the Company
     
       
As of December 31, 2022
   
754
 
As of December 31, 2021
   
353
 
 
 
Represents the officer’s gross salary, bonuses and vacation provisions without share based compensation.
 
  2.
Compensation of Key Officers of the Company:
 
The following amounts disclosed in the table are recognized as an expense during the reporting period related to officers:
 
   
Year ended December 31
 
   
2022
   
2021
   
2020
 
Short-term employee benefits (*)(**)
   
2,880
     
1,788
     
1,993
 
Share-based compensation
   
797
     
518
     
467
 
                         
     
3,677
     
2,306
     
2,460
 
Number of officers
   
7
     
5
     
5
 
 
(*) One-time expenses amounted $309 for the year ended December 31, 2022, are associated with the management changes.
 
(**) In December 2007, the Company's board of directors approved one‑time bonus payments to the Chief Medical Officer in the amounts of $120, which was recorded in profit and loss in December 2022 upon achieving marketing approval in the United States.